Previous 10 |
home / stock / cdmop / cdmop news
-- Achieved Fourth Quarter Revenue of $17.1 Million, an Increase of 146% Compared to Prior Year Quarter -- -- Generated Income From Continuing Operations During the Fourth Quarter of Fiscal 2019 -- -- Increasing Demand from Customers Expected to Drive Continued R...
TUSTIN, Calif., June 24, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology an...
-- Company to Provide Insight on Key CDMO Industry Topics through Podium Presentation, Panel Discussion and Executive Interview as Part of Convention’s BioProcess International Theater -- -- Corporate Booth to Highlight Company’s CDMO Service Offerings and State-of...
TUSTIN, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotech...
TUSTIN, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotech...
-- Achieved Revenue of $13.8 Million, an Increase of 102% Compared to Prior Year Quarter -- -- Signed Project Expansion Orders with Existing Customers Representing $23.8 Million -- -- Completed Process Validation Campaign for Future Commercial Production with Other Validations ...
TUSTIN, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology a...
TUSTIN, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology a...
News, Short Squeeze, Breakout and More Instantly...
Avid Bioservices Inc. 10.50% Series E Convertible Preferred Stock Company Name:
CDMOP Stock Symbol:
NASDAQ Market:
Avid Bioservices Inc. 10.50% Series E Convertible Preferred Stock Website:
-- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History -- -- Signed $30 Million in Net New Business Resulting in Backlog of $193 Million -- -- New Mammalian and Cell and Gene Therapy Facilities Fully Operational and in Service; Capital Expenditur...
TUSTIN, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announc...
TUSTIN, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and phar...